# YL-13027 in Patients With Advanced Solid Tumors

> **NCT05228600** · PHASE1 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** YL-13027

## Key facts

- **NCT ID:** NCT05228600
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-17
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228600, "YL-13027 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05228600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*